This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Carotuximab
- DrugBank Accession Number
- DB06322
- Background
Not Available
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Carotuximab
- Chimeric anti-CD105 antibody
- GAMMA1 HEAVY CHAIN (1-448) (MUS MUSCULUS VH (IGHV6-6*01-(IGHD) -IGHJ2*01) (8.10.9) (1-118) -HOMO SAPIENSIGHG1*01, GM17,1 (CH1 (119-216), HINGE (217-231), CH2(232-341), CH3 (342-446), CHS (447-448)) (119-448)), (221-213')-DISULFIDE WITH KAPPA LIGHT CHAIN
- IMMUNOGLOBULIN G1-KAPPA, ANTI-(HUMAN ENDOGLIN (CD105 ANTIGEN)) HUMAN MOUSE CHIMERIC MONOCLONAL ANTIBODY .GAMMA.1 HEAVY CHAIN (1-448) (MOUSE VH (MUS MUSCULUS IGHV6-6*01 (98%) (IGHD)-IGHJ2*01 (87%)) (8.10.9) (1-118) -HOMO SAPIENS IGHG1*01 (119-448)) (221-2
- IMMUNOGLOBULIN G1, ANTI-(HUMAN ENDOGLIN) (HUMAN-MUS MUSCULUS MONOCLONAL TRC105 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL TRC105 .KAPPA.-CHAIN, DIMER
- External IDs
- C-SN6J
- DE-122
- TRC 105
- TRC-105
- TRC105
Pharmacology
- Indication
Investigated for use/treatment in solid tumors.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
TRC105 is a first-in-class human chimeric monoclonal antibody that inhibits tumor growth by binding to CD105 (endoglin), a receptor over-expressed on proliferating endothelium that is required for angiogenesis (growth of new blood vessels). TRC105 has shown activity, as monotherapy or when combined with chemotherapy, in pre-clinical studies of breast and colorectal cancer. Pre-clinical data also indicate CD105 expression is increased following treatment of human cancer with anti-VEGF therapy. The target of TRC105 shares many features with the VEGF receptor. Most importantly, both the VEGF and CD105 receptors are essential for angiogenesis, in that deletion of either receptor prevents blood vessel formation in utero. [Traecon Pharmaceuticals Press Release]
Target Actions Organism UEndoglin Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Carotuximab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Carotuximab. Aducanumab The risk or severity of adverse effects can be increased when Carotuximab is combined with Aducanumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carotuximab. Alirocumab The risk or severity of adverse effects can be increased when Carotuximab is combined with Alirocumab. Amivantamab The risk or severity of adverse effects can be increased when Carotuximab is combined with Amivantamab. Anifrolumab The risk or severity of adverse effects can be increased when Carotuximab is combined with Anifrolumab. Ansuvimab The risk or severity of adverse effects can be increased when Carotuximab is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when Carotuximab is combined with Anthrax immune globulin human. Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Carotuximab is combined with Antilymphocyte immunoglobulin (horse). 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- YB2EWE6139
- CAS number
- 1268714-50-6
References
- General References
- Not Available
- External Links
- Wikipedia
- TRC105
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Advanced Angiosarcoma 1 2 Completed Treatment Age - Related Macular Degeneration (AMD) 1 2 Completed Treatment Cancer of the Ureter / Ureteral Cancer / Ureteral Neoplasms / Urothelial Carcinoma 1 2 Completed Treatment Choriocarcinoma 1 2 Completed Treatment Clear Cell Renal Cell Carcinoma / Renal Cell Carcinoma Recurrent / Stage IV Renal Cell Cancer / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma 1 2 Completed Treatment Fallopian Tube Carcinoma / Primary Peritoneal Carcinoma / Recurrent Ovarian Cancer 1 2 Completed Treatment Glioblastoma Multiforme (GBM) / High Grade Glioma: Glioblastoma (GBM) 1 2 Completed Treatment Hepatocellular Carcinoma / Liver Cancer 1 2 Completed Treatment Prostate Cancer 1 2 Not Yet Recruiting Treatment Castration Resistant Prostate Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Type ii transforming growth factor beta receptor binding
- Specific Function
- Major glycoprotein of vascular endothelium. Involved in the regulation of angiogenesis. May play a critical role in the binding of endothelial cells to integrins and/or other RGD receptors. Acts as...
- Gene Name
- ENG
- Uniprot ID
- P17813
- Uniprot Name
- Endoglin
- Molecular Weight
- 70577.325 Da
Drug created at March 19, 2008 16:24 / Updated at September 25, 2023 08:30